Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Next year, San Diego-based Ligand Pharmaceuticals is hoping to launch a third-generation selective estrogen receptor modulator (SERM) that it developed with Wyeth of Collegeville, Pennsylvania.